Oesophageal squamous cell carcinoma is a challenging form of cancer that affects the muscular tube connecting the throat to the stomach, requiring a highly personalized approach that combines surgery, radiation, chemotherapy, and increasingly, innovative immunotherapy treatments to control symptoms, slow progression, and improve quality of life.

Managing a Complex Cancer: Goals and Approaches

When someone is diagnosed with oesophageal squamous cell carcinoma, the treatment journey begins with understanding that every patient’s situation is unique. The main goals of treatment focus on several key areas: controlling symptoms such as difficulty swallowing, slowing the spread of the disease, and maintaining the best possible quality of life for as long as possible. In some cases, when the cancer is detected early, doctors aim to eliminate the tumor completely through surgery and other therapies.^[1]

Treatment decisions depend heavily on where the cancer is located within the esophagus—the upper, middle, or lower section—and how far it has spread. The stage of the disease, which describes whether cancer cells have moved beyond the esophagus into nearby tissues or lymph nodes, plays a crucial role in planning treatment. The grade of the cancer, which tells doctors how abnormal the cells look under a microscope, also influences the approach. Additionally, a patient’s overall health, fitness level, and personal preferences matter significantly when the medical team recommends a treatment plan.^[4]

Standard treatments for oesophageal squamous cell carcinoma have been refined over decades and include surgery, radiation therapy, and chemotherapy. These are often combined in different sequences to maximize effectiveness. However, the landscape of treatment is rapidly evolving. Medical researchers worldwide are testing new drugs and innovative therapies in clinical trials, offering hope for better outcomes. Immunotherapy, which helps the body’s own immune system fight cancer, has emerged as a particularly promising addition to the treatment toolkit in recent years.^[7]

The treatment approach should always be individualized. This means that decisions are made by an interdisciplinary tumor board—a team of specialists including surgeons, cancer doctors who specialize in drugs or radiation, nurses, dietitians, and other professionals—all working together to create the best plan for each patient. These teams consider not only the cancer itself but also the patient’s wishes, values, and what matters most to them in their daily life.^[13]

Standard Treatment Approaches

Surgery: Removing the Tumor

Surgery remains one of the most common treatments for oesophageal squamous cell carcinoma, particularly when the cancer has not spread to distant parts of the body. The type of surgery depends on the size and location of the tumor. For very early-stage cancers confined to the inner lining of the esophagus, doctors may perform an endoscopic resection. This is a minimally invasive procedure where a flexible tube with a camera and cutting tools is passed down the throat, allowing the surgeon to remove the cancerous tissue without making external incisions.^[11]

Two main types of endoscopic procedures are used: endoscopic mucosal resection and endoscopic submucosal dissection. These techniques are suitable for small tumors that have not grown deeply into the esophageal wall. After the cancerous tissue is removed, patients may need additional ablation therapy, which uses heat or other energy to destroy any remaining abnormal cells. However, endoscopic procedures can lead to complications, particularly when larger areas are treated. Bleeding, perforation of the esophageal wall, and narrowing of the esophagus due to scar tissue formation are possible side effects. When strictures develop, they typically appear two to four weeks after the procedure and can cause progressive difficulty swallowing, potentially leading to malnutrition.^[11]

For more advanced but still localized cancers, a major surgery called esophagectomy may be necessary. This operation involves removing all or part of the esophagus, and sometimes the upper portion of the stomach as well. There are different surgical approaches: transthoracic (through the chest), transhiatal (through the abdomen and a small neck incision), or increasingly, minimally invasive techniques using small incisions and specialized instruments. After removing the diseased portion, surgeons reconstruct the digestive tract, typically using the stomach to create a tube-like structure called a gastric conduit that connects the remaining esophagus to the stomach or intestine.^[5]

The decision to pursue surgery depends not only on the cancer’s characteristics but also on the patient’s overall fitness and ability to tolerate a major operation. Recovery from esophagectomy is significant and requires careful nutritional support, often including a feeding tube placed directly into the intestine to ensure adequate nutrition while healing occurs.^[11]

Chemotherapy: Targeting Cancer Throughout the Body

Chemotherapy uses powerful drugs to destroy cancer cells throughout the body. These cytotoxic drugs circulate in the bloodstream and can reach cancer cells that may have spread beyond the esophagus. For oesophageal squamous cell carcinoma, chemotherapy is rarely used alone; instead, it is typically combined with other treatments to maximize effectiveness.^[12]

The most common chemotherapy combination for this type of cancer pairs a platinum-based drug—such as cisplatin or carboplatin—with either a fluoropyrimidine (like 5-fluorouracil or capecitabine) or paclitaxel, a drug that interferes with cell division. This combination is often given before surgery to shrink the tumor, making it easier to remove. This approach is called neoadjuvant chemotherapy. Shrinking the tumor before surgery may also reduce the chance that microscopic cancer cells remain after the operation.^[4]

Chemotherapy may also be given after surgery, called adjuvant chemotherapy, to eliminate any remaining cancer cells. In cases where surgery is not possible or the cancer has spread to other organs, chemotherapy serves as the main treatment to control the disease, relieve symptoms, and improve quality of life. When used for advanced or metastatic disease, chemotherapy can help extend survival, though it does not cure the cancer.^[12]

The duration of chemotherapy treatment varies. Neoadjuvant regimens typically last several weeks to a few months before surgery. For advanced disease, treatment may continue for many months, with regular breaks to allow the body to recover. The specific schedule depends on how well the cancer responds and how the patient tolerates the drugs.^[7]

Side effects of chemotherapy are common and can significantly impact daily life. These drugs affect rapidly dividing cells throughout the body, not just cancer cells. Common side effects include nausea and vomiting, fatigue, hair loss, increased risk of infections due to lower white blood cell counts, and mouth sores. Platinum drugs can cause nerve damage leading to numbness or tingling in the hands and feet, while fluoropyrimidines may cause diarrhea and hand-foot syndrome, where the palms and soles become red, swollen, and painful. Most side effects are temporary and resolve after treatment ends, though some, like nerve damage, may be long-lasting.^[1]

Radiation Therapy: Targeting the Tumor Precisely

Radiation therapy uses high-energy rays to destroy cancer cells. For oesophageal squamous cell carcinoma, radiation is almost always combined with chemotherapy in an approach called chemoradiotherapy or chemoradiation. The chemotherapy drugs make the cancer cells more sensitive to radiation, enhancing the treatment’s effectiveness.^[8]

Chemoradiotherapy can be used in several ways. It may be given before surgery to shrink the tumor, increasing the likelihood of successful removal and reducing the chance of cancer recurring after the operation. For patients with tumors in the upper or middle esophagus, or for those who cannot undergo surgery due to other health conditions, chemoradiotherapy may be the primary treatment with the goal of eliminating the cancer without surgery. This approach is called definitive chemoradiotherapy.^[13]

Modern radiation therapy techniques have become increasingly sophisticated. Intensity-Modulated Radiation Therapy (IMRT) is a particularly advanced approach that shapes the radiation beams to precisely match the tumor’s contours. This precision is crucial for esophageal cancer because the esophagus sits very close to vital organs like the heart and lungs. By concentrating the radiation on the tumor while minimizing exposure to surrounding healthy tissue, IMRT reduces the risk of damage to these organs.^[15]

A typical radiation treatment course for esophageal cancer involves daily sessions, Monday through Friday, for five to six weeks. Each session lasts only a few minutes, though the entire appointment may take longer due to positioning and setup. Before treatment begins, patients undergo a simulation session where detailed CT scans map the exact location of the tumor. The radiation therapy team uses these images to plan the treatment with millimeter precision, ensuring that each daily dose is delivered to exactly the right location.^[15]

Side effects from radiation to the esophagus can be significant. Esophagitis, or inflammation of the esophagus, is common and causes pain with swallowing. This can make eating difficult and lead to weight loss. Fatigue is nearly universal during radiation treatment and may persist for weeks after treatment ends. Nausea may occur, particularly when radiation affects the lower esophagus near the stomach. Long-term side effects can include scarring that narrows the esophagus, requiring procedures to stretch it open, and potential damage to the heart or lungs if these organs received radiation exposure, though modern techniques have greatly reduced this risk.^[15]

Combined Treatment Strategies

For locally advanced oesophageal squamous cell carcinoma—meaning the tumor is large or has spread to nearby lymph nodes but has not reached distant organs—the standard approach combines multiple treatments. The most common strategy is chemoradiotherapy followed by surgery. This sequence, sometimes called trimodality therapy, offers the best chance for long-term disease control in appropriate patients.^[4]

After completing chemoradiotherapy and undergoing surgery, doctors examine the removed tissue to determine whether any cancer cells remain. If the surgery achieved R0 resection, meaning no cancer is visible at the edges of the removed tissue, and if there is still evidence of cancer (not a complete pathological response), newer guidelines recommend additional treatment with immunotherapy for one year. This adjuvant approach has been shown to improve disease-free survival.^[7]

For patients with tumors in the cervical (upper) esophagus, the treatment approach differs slightly. Surgery in this location is particularly challenging and carries higher risks, so definitive chemoradiotherapy without surgery is often the preferred approach.^[11]

Innovative Treatments in Clinical Trials

Immunotherapy: Harnessing the Body’s Defenses

The most significant recent advance in treating oesophageal squamous cell carcinoma has been the introduction of immunotherapy. These drugs do not directly attack cancer cells. Instead, they work by removing the brakes from the body’s immune system, allowing it to recognize and destroy cancer cells more effectively.^[7]

Cancer cells often evade the immune system by exploiting checkpoint proteins, which normally prevent the immune system from attacking the body’s own cells. Two important checkpoints are programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1). When cancer cells display PD-L1 on their surface, they can bind to PD-1 on immune cells, essentially telling the immune system to leave them alone. Checkpoint inhibitors are drugs that block these interactions, unleashing the immune system to attack the cancer.^[7]

Several checkpoint inhibitors have been tested in clinical trials for oesophageal squamous cell carcinoma, and some have gained regulatory approval. For patients with advanced or metastatic disease, combining immunotherapy with standard chemotherapy has become a new standard of care in many regions. In Europe, this combination approach is approved for patients whose tumors show PD-L1 positivity. In the United States, checkpoint inhibitors combined with chemotherapy are approved for all patients with advanced esophageal squamous cell carcinoma, regardless of PD-L1 status.^[7]

The way PD-L1 levels are measured and reported varies. Two scoring systems are commonly used: the Tumor Proportion Score (TPS), which measures the percentage of tumor cells expressing PD-L1, and the Combined Positive Score (CPS), which accounts for PD-L1 expression on tumor cells, immune cells, and other cells in the tumor environment. European guidelines typically use thresholds of TPS ≥1% or CPS ≥10 to determine eligibility for immunotherapy.^[7]

Immunotherapy has also been approved for use after chemoradiotherapy and surgery. For patients who did not achieve a complete pathological response but had successful R0 resection, one year of adjuvant immunotherapy has been shown to improve disease-free survival, meaning patients live longer without the cancer returning.^[13]

For patients whose cancer progresses after initial treatment, immunotherapy may be used as a second-line treatment. However, an important question remains under investigation: if a patient received immunotherapy as part of their first-line treatment and the cancer progressed, should they receive immunotherapy again as second-line treatment, or should they switch to standard chemotherapy with drugs like taxanes or irinotecan? Current practice generally favors switching to chemotherapy after progression on immunotherapy, as the benefit of reintroducing immune checkpoint inhibitors is not yet established.^[7]

The side effects of immunotherapy differ markedly from those of chemotherapy. Because these drugs activate the immune system, they can sometimes cause the immune system to attack normal tissues, leading to immune-related adverse events. These can affect almost any organ system. Common side effects include skin rashes, diarrhea and inflammation of the intestines, inflammation of the liver or thyroid gland, and less commonly, inflammation of the lungs, kidneys, or other organs. Most immune-related side effects are manageable with medications that suppress the immune response, such as corticosteroids, but they require careful monitoring. Some patients experience fatigue, which can be persistent. Unlike chemotherapy side effects that typically improve shortly after stopping treatment, some immune-related adverse events can persist for months or even become permanent.^[1]

Understanding Clinical Trial Phases

When new drugs and treatments are being developed, they progress through a structured series of clinical trials before becoming widely available. Understanding these phases helps patients appreciate where a particular therapy stands in the development process.^[1]

Phase I trials are the first time a new treatment is tested in humans. These studies primarily focus on safety: determining the appropriate dose, identifying side effects, and understanding how the drug behaves in the body. Phase I trials typically involve a small number of patients, sometimes fewer than 30. While the primary goal is not to measure effectiveness, researchers carefully observe whether the treatment shows any signs of working against the cancer.

Phase II trials expand testing to a larger group of patients, typically 50 to 200, with the primary goal of determining whether the treatment is effective against the specific type of cancer. Researchers measure response rates, looking at how many patients’ tumors shrink or stop growing. They also continue to collect safety information. A drug must show promising results in Phase II trials to justify the expense and effort of larger Phase III studies.

Phase III trials are large studies, often involving hundreds or thousands of patients, that compare the new treatment directly against the current standard treatment. These trials provide the strongest evidence about whether the new treatment is better than existing options. Patients are randomly assigned to receive either the new treatment or the standard treatment, and neither the patients nor their doctors choose which group they’re in. Phase III trials measure important outcomes like survival, disease-free survival, and quality of life. Positive results from Phase III trials are typically required for regulatory approval by agencies like the FDA in the United States or the European Medicines Agency in Europe.

Targeted Therapies and Emerging Approaches

Beyond checkpoint inhibitors, researchers are investigating other innovative approaches to treating oesophageal squamous cell carcinoma. Targeted therapies are drugs designed to interfere with specific molecules involved in cancer growth and survival. Unlike chemotherapy, which affects all rapidly dividing cells, targeted therapies aim to exploit unique characteristics of cancer cells, potentially causing fewer side effects.^[12]

For some cancers, including certain esophageal cancers, researchers look for specific genetic changes or protein expressions that can be targeted. For example, some tumors have high levels of a protein called HER2 on their surface. Drugs that specifically target HER2 have been developed and tested. While HER2 targeting is more commonly used in esophageal adenocarcinoma, research continues to identify targetable changes in squamous cell carcinoma as well.^[4]

Another area of investigation involves drugs that target blood vessel formation. Tumors need blood vessels to supply them with nutrients and oxygen. Anti-angiogenic drugs work by preventing the formation of new blood vessels, potentially starving the tumor. Several such drugs are being tested in combination with chemotherapy and immunotherapy for esophageal cancers.

Clinical trials for oesophageal squamous cell carcinoma are being conducted at major cancer centers worldwide, including sites in the United States, Europe, and Asia. Patient eligibility for clinical trials depends on many factors, including the stage of cancer, previous treatments received, overall health status, and specific characteristics of the tumor. Not every patient is eligible for every trial, but clinical trials offer access to promising new treatments before they become widely available.^[1]

Most common treatment methods

• Endoscopic treatments
  • Endoscopic mucosal resection removes early-stage tumors confined to the inner lining of the esophagus using instruments passed through a flexible tube inserted down the throat.^[11]
  • Endoscopic submucosal dissection allows removal of slightly larger early tumors by cutting deeper into the esophageal wall layers.^[11]
  • Ablation therapy uses heat or other energy to destroy abnormal cells remaining after tumor removal or to treat precancerous changes.^[11]
• Surgical approaches
  • Esophagectomy removes all or part of the esophagus through transthoracic, transhiatal, or minimally invasive approaches, with reconstruction using the stomach or intestine.^[5]
  • Gastric conduit reconstruction creates a tube-like structure from the stomach to replace the removed esophagus and restore digestive continuity.^[11]
• Chemotherapy regimens
  • Platinum-fluoropyrimidine combinations pair cisplatin or carboplatin with 5-fluorouracil or capecitabine to attack cancer cells throughout the body.^[4]
  • Platinum-taxane regimens combine cisplatin or carboplatin with paclitaxel, offering an alternative chemotherapy backbone.^[4]
  • Second-line chemotherapy with taxanes or irinotecan provides options when initial treatment stops working.^[7]
• Radiation therapy
  • Intensity-Modulated Radiation Therapy precisely shapes radiation beams to target the tumor while minimizing exposure to the heart and lungs.^[15]
  • Chemoradiotherapy combines radiation with chemotherapy drugs to enhance cancer cell destruction, used before surgery or as definitive treatment.^[8]
• Immunotherapy
  • Checkpoint inhibitors targeting PD-1 or PD-L1 proteins remove immune system brakes, allowing the body to recognize and attack cancer cells.^[7]
  • First-line immunotherapy combinations pair checkpoint inhibitors with platinum-fluoropyrimidine chemotherapy for advanced disease.^[7]
  • Adjuvant immunotherapy for one year after surgery and chemoradiotherapy improves disease-free survival in patients without complete pathological response.^[13]
• Palliative treatments
  • Esophageal stent placement opens narrowed sections of the esophagus to relieve swallowing difficulties in advanced cancer.^[22]
  • Palliative radiation therapy relieves pain and bleeding, and improves swallowing in patients with advanced disease.^[22]
  • Nutritional support through feeding tubes ensures adequate nutrition when swallowing becomes impossible or unsafe.^[11]